Alzheimer's Disease/Cognition News

The FDA’s approval of Leqembi in July 2023 triggered a wave of discussion in the medical community on how to prescribe and properly administer the amyloid-targeting antibody to treat those diagnosed with Alzheimer’s disease.

DENVER — A panel of four experts discussed different aspects of the ways brain health and climate change are linked at the American Academy of Neurology annual meeting.

DENVER — Treatment with a novel, oral receptor agonist led to rapid and significant improvements in those with agitation related to Alzheimer’s disease, according to a speaker at the American Academy of Neurology annual meeting.

Dementia risk decreases among patients with rheumatoid arthritis treated with biologic disease-modifying antirheumatic drugs, according to a systematic review and meta-analysis published in RMD Open.

Labcorp and Quest Diagnostics have both announced the availability of blood-based biomarker testing for Alzheimer’s disease, one which detects glial fibrillary acidic protein and another for phosphorylated tau.

The FDA has granted breakthrough device designation to a blood-based biomarker test to more quickly detect amyloid presence in individuals with suspected Alzheimer’s disease, according to the manufacturer.

DENVER — While rare and associated with a limited differential diagnosis, abrupt-onset dementia may be treatable with prompt recognition and early intervention, according to a poster at the American Academy of Neurology annual meeting.

DENVER — The American Brain Foundation is funding research to find a cure for Lewy body dementia and discover breakthroughs in neuroinflammation, the group’s executive director said at the American Academy of Neurology annual meeting.

DENVER – Location of residence was not associated with subjective cognitive decline in Black women, suggesting the Area Deprivation Index may not be a reliable measurement, according to a speaker.

The ability to reason and solve new problems, known as fluid cognition, is lower among patients with systemic lupus erythematosus compared with the general population, according to data published in Arthritis Care & Research.